Evidence map›Paper›PMID 25730191›Full record

Trial reportBone marrow transplantation2015

Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy.

M Tanaka, H Kanamori, K Matsumoto, T Tachibana, A Numata, K Ohashi, T Kobayashi, C Nakaseko, Y Kanda, E Yamazaki and 16 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

M TanakaDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
H KanamoriDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
K MatsumotoDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
T Tachibana1] Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan [2] Department of Hematology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
A Numata1] Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan [2] Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
K OhashiDivision of Hematology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan.
T KobayashiDivision of Hematology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan.
C NakasekoDivision of Hematology, Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Chiba, Japan.
Y KandaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
E YamazakiDepartment of Hematology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
S FujisawaDepartment of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
J OoiDivision of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
T SakuraLeukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
N AotsukaDepartment of Hematology, Narita Red Cross Hospital, Narita, Japan.
M OnodaDepartment of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan.
S MachidaDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
J KatoDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
K UsukiDivision of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
R WatanabeDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
J TaguchiDepartment of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan.
S YanoDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
T SaitoDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
S TakahashiDivision of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
H SakamakiDepartment of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
S OkamotoDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Kanto Study Group for Cell Therapy

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This prospective study aimed to investigate the influence of pretransplant serum ferritin levels on the outcomes of allogeneic hematopoietic SCT (HSCT). In total, 190 patients with acute leukemia or myelodysplastic syndrome were consecutively enrolled. The patients were divided into two groups: low-ferritin group (<1000 ng/mL) and high-ferritin group (⩾1000 ng/mL). The primary end point was the cumulative incidence of infection within 100 days after HSCT, which was similar between the two groups: bloodstream infection, 35 vs 38%, P=0.65; bacterial infection, 44 vs 41%, P=0.68; and fungal infection, 6 vs 8%, P=0.71. The 1-year adjusted probability of OS of the high-ferritin group was significantly lower than that of the low-ferritin group (76 vs 63%, P=0.017). Using receiver operating characteristic curve, the threshold of pretransplant serum ferritin levels for bloodstream infection was 1400 ng/mL; the threshold for OS, EFS and non-relapse mortality was 1349 ng/mL. In conclusion, pretransplant serum ferritin levels of ⩾1000 ng/mL did not influence the incidence of infection but adversely affected OS after HSCT. A higher threshold of pretransplant serum ferritin levels may predict HSCT outcomes.

Indexed as

Bacterial InfectionsHematologic NeoplasmsHematopoietic Stem Cell TransplantationMycosesPreoperative PeriodAdultAgedAllograftsDisease-Free SurvivalFemaleFerritinsFollow-Up StudiesHumansIncidenceMaleMiddle AgedFerritins

Identifiers

PMID25730191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.